Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 Patients

Wilma Barcellini, Bruno Fattizzo, Anna Zaninoni, Tommaso Radice, Ilaria Nichele, Eros Di Bona, Monia Lunghi, Cristina Tassinari, Fiorella Alfinito, Antonella Ferrari, Anna Paola Leporace, Pasquale Niscola, Monica Carpenedo, Carla Boschetti, Nicoletta Revelli, Maria Antonietta Villa, Dario Consonni, Laura Scaramucci, Paolo De Fabritiis, Giuseppe TagarielloGianluca Gaidano, Francesco Rodeghiero, Agostino Cortelezzi, Alberto Zanella

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

The clinical outcome, response to treatment, and occurrence of acute complications were retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated with serological characteristics and severity of anemia at onset. Patients had been followedup for a median of 33 months (range12-372); 60% were warm AIHA, 27% cold hemagglutinin disease, 8% mixed, and 5% atypical (mostly direct antiglobulin test negative). The latter 2 categories more frequently showed a severe onset (hemoglobin [Hb] levels ≤6 g/dL) along with reticulocytopenia. The majority of warm AIHA patients received first-line steroid therapy only, whereas patients with mixed and atypical forms were more frequently treated with 2 or more therapy lines, including splenectomy, immunosuppressants, and rituximab. The cumulative incidenceofrelapse was increasedin more severe cases (hazard ratio 3.08;95% confidence interval, 1.44-6.57 for Hb ≤6 g/dL; P

Original languageEnglish
Pages (from-to)2930-2936
Number of pages7
JournalBlood
Volume124
Issue number19
DOIs
Publication statusPublished - Nov 6 2014

Fingerprint

Autoimmune Hemolytic Anemia
Hemoglobins
Hemagglutinins
Immunosuppressive Agents
Coombs Test
Anti-Idiotypic Antibodies
Hazards
Steroids
Splenectomy
Anemia
Therapeutics
Confidence Intervals
Rituximab

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology
  • Medicine(all)

Cite this

Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia : A GIMEMA study of 308 Patients. / Barcellini, Wilma; Fattizzo, Bruno; Zaninoni, Anna; Radice, Tommaso; Nichele, Ilaria; Di Bona, Eros; Lunghi, Monia; Tassinari, Cristina; Alfinito, Fiorella; Ferrari, Antonella; Leporace, Anna Paola; Niscola, Pasquale; Carpenedo, Monica; Boschetti, Carla; Revelli, Nicoletta; Villa, Maria Antonietta; Consonni, Dario; Scaramucci, Laura; De Fabritiis, Paolo; Tagariello, Giuseppe; Gaidano, Gianluca; Rodeghiero, Francesco; Cortelezzi, Agostino; Zanella, Alberto.

In: Blood, Vol. 124, No. 19, 06.11.2014, p. 2930-2936.

Research output: Contribution to journalArticle

Barcellini, W, Fattizzo, B, Zaninoni, A, Radice, T, Nichele, I, Di Bona, E, Lunghi, M, Tassinari, C, Alfinito, F, Ferrari, A, Leporace, AP, Niscola, P, Carpenedo, M, Boschetti, C, Revelli, N, Villa, MA, Consonni, D, Scaramucci, L, De Fabritiis, P, Tagariello, G, Gaidano, G, Rodeghiero, F, Cortelezzi, A & Zanella, A 2014, 'Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 Patients', Blood, vol. 124, no. 19, pp. 2930-2936. https://doi.org/10.1182/blood-2014-06-583021
Barcellini, Wilma ; Fattizzo, Bruno ; Zaninoni, Anna ; Radice, Tommaso ; Nichele, Ilaria ; Di Bona, Eros ; Lunghi, Monia ; Tassinari, Cristina ; Alfinito, Fiorella ; Ferrari, Antonella ; Leporace, Anna Paola ; Niscola, Pasquale ; Carpenedo, Monica ; Boschetti, Carla ; Revelli, Nicoletta ; Villa, Maria Antonietta ; Consonni, Dario ; Scaramucci, Laura ; De Fabritiis, Paolo ; Tagariello, Giuseppe ; Gaidano, Gianluca ; Rodeghiero, Francesco ; Cortelezzi, Agostino ; Zanella, Alberto. / Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia : A GIMEMA study of 308 Patients. In: Blood. 2014 ; Vol. 124, No. 19. pp. 2930-2936.
@article{d5854aac4dee4295933ddcdf6f619817,
title = "Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: A GIMEMA study of 308 Patients",
abstract = "The clinical outcome, response to treatment, and occurrence of acute complications were retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated with serological characteristics and severity of anemia at onset. Patients had been followedup for a median of 33 months (range12-372); 60{\%} were warm AIHA, 27{\%} cold hemagglutinin disease, 8{\%} mixed, and 5{\%} atypical (mostly direct antiglobulin test negative). The latter 2 categories more frequently showed a severe onset (hemoglobin [Hb] levels ≤6 g/dL) along with reticulocytopenia. The majority of warm AIHA patients received first-line steroid therapy only, whereas patients with mixed and atypical forms were more frequently treated with 2 or more therapy lines, including splenectomy, immunosuppressants, and rituximab. The cumulative incidenceofrelapse was increasedin more severe cases (hazard ratio 3.08;95{\%} confidence interval, 1.44-6.57 for Hb ≤6 g/dL; P",
author = "Wilma Barcellini and Bruno Fattizzo and Anna Zaninoni and Tommaso Radice and Ilaria Nichele and {Di Bona}, Eros and Monia Lunghi and Cristina Tassinari and Fiorella Alfinito and Antonella Ferrari and Leporace, {Anna Paola} and Pasquale Niscola and Monica Carpenedo and Carla Boschetti and Nicoletta Revelli and Villa, {Maria Antonietta} and Dario Consonni and Laura Scaramucci and {De Fabritiis}, Paolo and Giuseppe Tagariello and Gianluca Gaidano and Francesco Rodeghiero and Agostino Cortelezzi and Alberto Zanella",
year = "2014",
month = "11",
day = "6",
doi = "10.1182/blood-2014-06-583021",
language = "English",
volume = "124",
pages = "2930--2936",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "19",

}

TY - JOUR

T1 - Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia

T2 - A GIMEMA study of 308 Patients

AU - Barcellini, Wilma

AU - Fattizzo, Bruno

AU - Zaninoni, Anna

AU - Radice, Tommaso

AU - Nichele, Ilaria

AU - Di Bona, Eros

AU - Lunghi, Monia

AU - Tassinari, Cristina

AU - Alfinito, Fiorella

AU - Ferrari, Antonella

AU - Leporace, Anna Paola

AU - Niscola, Pasquale

AU - Carpenedo, Monica

AU - Boschetti, Carla

AU - Revelli, Nicoletta

AU - Villa, Maria Antonietta

AU - Consonni, Dario

AU - Scaramucci, Laura

AU - De Fabritiis, Paolo

AU - Tagariello, Giuseppe

AU - Gaidano, Gianluca

AU - Rodeghiero, Francesco

AU - Cortelezzi, Agostino

AU - Zanella, Alberto

PY - 2014/11/6

Y1 - 2014/11/6

N2 - The clinical outcome, response to treatment, and occurrence of acute complications were retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated with serological characteristics and severity of anemia at onset. Patients had been followedup for a median of 33 months (range12-372); 60% were warm AIHA, 27% cold hemagglutinin disease, 8% mixed, and 5% atypical (mostly direct antiglobulin test negative). The latter 2 categories more frequently showed a severe onset (hemoglobin [Hb] levels ≤6 g/dL) along with reticulocytopenia. The majority of warm AIHA patients received first-line steroid therapy only, whereas patients with mixed and atypical forms were more frequently treated with 2 or more therapy lines, including splenectomy, immunosuppressants, and rituximab. The cumulative incidenceofrelapse was increasedin more severe cases (hazard ratio 3.08;95% confidence interval, 1.44-6.57 for Hb ≤6 g/dL; P

AB - The clinical outcome, response to treatment, and occurrence of acute complications were retrospectively investigated in 308 primary autoimmune hemolytic anemia (AIHA) cases and correlated with serological characteristics and severity of anemia at onset. Patients had been followedup for a median of 33 months (range12-372); 60% were warm AIHA, 27% cold hemagglutinin disease, 8% mixed, and 5% atypical (mostly direct antiglobulin test negative). The latter 2 categories more frequently showed a severe onset (hemoglobin [Hb] levels ≤6 g/dL) along with reticulocytopenia. The majority of warm AIHA patients received first-line steroid therapy only, whereas patients with mixed and atypical forms were more frequently treated with 2 or more therapy lines, including splenectomy, immunosuppressants, and rituximab. The cumulative incidenceofrelapse was increasedin more severe cases (hazard ratio 3.08;95% confidence interval, 1.44-6.57 for Hb ≤6 g/dL; P

UR - http://www.scopus.com/inward/record.url?scp=84909592643&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909592643&partnerID=8YFLogxK

U2 - 10.1182/blood-2014-06-583021

DO - 10.1182/blood-2014-06-583021

M3 - Article

C2 - 25232059

AN - SCOPUS:84909592643

VL - 124

SP - 2930

EP - 2936

JO - Blood

JF - Blood

SN - 0006-4971

IS - 19

ER -